Thursday thought on $DMRC, $BIOC

Ok, the bear got the ball in the first week of 2016 hoping for a “shock & awe” attack.  Somehow, this drop didn’t feel “lethal” as the last August drop.  Once the bear run out of ammunition, the bull will roar right back which will frustrate the bear to no end.  The smart short will start to cover soon.  Me no worry here.

In fact, my trusty $DMRC got news!

Global Health Care Supplier Perrigo Adopts Digimarc Barcode for Enhanced Consumer Information and Retailer Point-of-Sale Efficiency

Below excerpt (with my underline as emphasis) reflects the most IMPORTANT piece of information regarding the Digimarc revolution:

Digimarc Corp. (DMRC) today announced a collaboration with Perrigo Company (PRGO), the world’s largest manufacturer of over-the-counter pharmaceutical products for the store brand market. Perrigo is joining other leading suppliers as a Digimarc channel partner to enable it to provide Digimarc Barcode services to its retail customers.

Listen, the world’s LARGEST manufacturer of over-the-counter pharmaceutical products is jumping on board the Digimarc wagon, how long do you think it will take for the other competitors to come on board the wagon as well?  Imagine you are a customer at Walmart, you point your phone to one of the Perrigo’s OTC drug bottles and a load of relevant information appears in front of you.  Then you point your phone to the competitor’s brand and “NOTHING” comes out.  “What’s the h**!”  What is the likelihood you are going to pick the brand that you just pinned successfully with the phone?

This is just the beginning of an avalanche that is going to slide down the mountain and cover the whole town with Digimarc snowflakes.  The shorts should be afraid.  Very afraid even.  The coming onslaught of news will be non-stop.  Don’t forget the January 17th Big Retail Show.  Who is going to be in the booth with Digimarc?  Can’t wait to find out.

$BIOC also got news!

Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer

Below is an excerpt with my underline as emphasis:

The Biocept assay uses circulating tumor cells (CTCs) from a simple blood draw to detect androgen receptor expression, which is prevalent in patients with advanced prostate cancer.  Prostate cancer is the second leading cause of male cancer-related death and the second most commonly diagnosed cancer among men in the U.S. with 220,800 cases identified in 2014, according to the American Cancer Society.  Approximately one in every seven men in the U.S. will be diagnosed with prostate cancer during his lifetime.

If Biocept wins this prostate cancer diagnostic test war and dominate the field, watch out!

So far so good!

My 2 cents

From my camera:



Categories: Daily trading Journal, trading journal

Tags: , ,

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: